Glaukos Corporation

GKOS Healthcare Medical Devices

Glaukos Corporation’s revenue for fiscal 2025 (year ended December 2025) was $507.4 million, up 32.3% from fiscal 2024.

Revenue
+58.0%
EPS
+110.7%
Free cash flow
+411.2%
Total debt
−2.25%

Quarter to September 2026, against a year earlier

225.48 5.50 +2.50%
Market cap
$13.0B
P/E
0.0×
Fwd P/E
−803×
Dividend yield
—
F-score
3/9
Altman Z
15.20
Beneish M
−2.96
Dividend safety
n/a

Glaukos Corporation (GKOS) Gross margin

Alert me on Gross margin

Glaukos Corporation's gross margin over the twelve months to 30 September 2026 was 81.1%, up 3.2 percentage points from fiscal 2025 (78.0%). Over the past ten years it has ranged from 59.2% (fiscal 2020) to 86.8% (fiscal 2017); the current reading is higher than 55% of that period. That is above the Medical Devices industry median of 57.8% and above the Healthcare sector median of 53.9%.

Gross margin, annual

Embed this chart

Annual newest first

Period Gross margin Change (points)
FY2025 78.0% 2.49
FY2024 75.5% (0.51)
FY2023 76.0% 0.38
FY2022 75.6% (1.73)
FY2021 77.3% 18.11
FY2020 59.2% (24.49)
FY2019 83.7% (2.45)
FY2018 86.2% (0.61)
FY2017 86.8% 0.92
FY2016 85.9% 3.97

Quarterly newest first

Period Gross margin Change (points)
Sep 2026 85.2% 3.56
Jun 2026 81.7% 3.81
Mar 2026 77.9% 0.06
Dec 2025 77.8% (0.61)
43 more quarters

Against its own ten years

Low 59.2% High 86.8%
Ten-year median 78.0%
Current reading's percentile 63

Gross margin against peers

What Gross margin is

Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.

Gross Profit ÷ Revenue

The full definition of Gross margin →

More on GKOS